B. Riley analyst Yuan Zhi lowered the firm’s price target on Hyperfine (HYPR) to $1.20 from $1.50 and keeps a Buy rating on the shares. The top-line miss in in Q4 was driven by extended timelines in legacy critical care business, and guidance for the first half of 2025 implies a continued slowdown, while 2025 guidance implies a sharp revenue increase in the second half of the year, the analyst tells investors in a research note. Uncertainty remains, and management will have more visibility in the coming months amid new sales reps and new opportunities, the firm adds.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HYPR:
- Hyperfine Inc. Faces Potential Stock Price Decline Amid $150 Million Securities Sale Plan
- Hyperfine Inc. Earnings Call: Growth Amid Challenges
- Hyperfine, Inc. Reports 2024 Financial Results and Strategic Expansion
- Hyperfine sees FY25 revenue growth 20%- 30% over 2024, consensus $17M
- Hyperfine reports Q4 EPS (14c), consensus (14c)
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue